June 1, 2020
View Archives Issues
COVID-19 is a systemic disease that primarily injures the vascular endothelium, causing a unique lung injury in which different management strategies may need to be considered to address the specific physiology of each patient.
In a retrospective study involving 449 patients with severe COVID-19 requiring intensive care unit admission, those patients with a positive sepsis coagulation score or D-dimer greater than 3.0 mcg/mL who received prophylactic doses of low molecular weight heparin exhibited lower 28-day mortality.
In this group of patients hospitalized with severe COVID-19, the majority of whom required invasive ventilation, 68% showed clinical improvement after treatment with remdesivir on a compassionate-use basis.